These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 10472556)

  • 1. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
    Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
    Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
    Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
    J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
    Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
    Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia.
    Hongo T; Yamada S; Yajima S; Watanabe C; Fujii Y; Kawasaki H; Yazaki M; Hanada R; Horikoshi Y
    Int J Hematol; 1999 Dec; 70(4):268-77. PubMed ID: 10643153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
    Ishii E; Eguchi H; Matsuzaki A; Koga H; Yanai F; Kuroda H; Kawakami K; Ayukawa H; Akiyoshi K; Kamizono J; Tamai Y; Kinukawa N; Okamura J
    Med Pediatr Oncol; 2001 Jul; 37(1):10-9. PubMed ID: 11466717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
    Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
    Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
    Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
    Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
    Styczynski J; Piatkowska M; Jaworska-Posadzy A; Czyzewski K; Kubicka M; Kolodziej B; Kurylo-Rafinska B; Debski R; Pogorzala M; Wysocki M
    Anticancer Res; 2012 Dec; 32(12):5495-9. PubMed ID: 23225457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97.
    Escherich G; Horstmann MA; Zimmermann M; Janka-Schaub GE;
    Leukemia; 2010 Feb; 24(2):298-308. PubMed ID: 20016530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
    Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
    Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis.
    Styczynski J; Koltan A; Wysocki M
    Neoplasma; 2006; 53(2):168-73. PubMed ID: 16575474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
    Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
    Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
    Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment for a high-risk group for childhood acute lymphoblastic leukemia].
    Koizumi S
    Gan To Kagaku Ryoho; 1999 Jul; 26(8):1042-9. PubMed ID: 10431575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
    J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.